A NOVEL PATHOGENIC ROLE FOR GALECTIN-3 IN EARLY DISEASE STAGES OF ARRHYTHMOGENIC CARDIOMYOPATHY.

[1]  D. Alavantic,et al.  Left ventricular remodeling after the first myocardial infarction in association with LGALS-3 neighbouring variants rs2274273 and rs17128183 and its relative mRNA expression: a prospective study , 2018, Molecular Biology Reports.

[2]  J. Healey,et al.  An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis , 2018, European heart journal.

[3]  P. Boor,et al.  Desmoglein 2, but not desmocollin 2, protects intestinal epithelia from injury , 2018, Mucosal Immunology.

[4]  N. Arsenijević,et al.  Galectin-3 deficiency enhances type 2 immune cell-mediated myocarditis in mice , 2018, Immunologic Research.

[5]  S. Toppo,et al.  Loss of cardiac Wnt/&bgr;-catenin signalling in desmoplakin-deficient AC8 zebrafish models is rescuable by genetic and pharmacological intervention , 2018, Cardiovascular research.

[6]  Andrew J Taylor,et al.  Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure , 2018, Scientific Reports.

[7]  Jian Zhang,et al.  Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population. , 2018, Gene.

[8]  L. Lavra,et al.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z , 2018, International journal of molecular sciences.

[9]  R. D. de Boer,et al.  Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update , 2018, Theranostics.

[10]  N. Dang,et al.  Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. , 2017, Journal of autoimmunity.

[11]  K. Adalet,et al.  Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular arrhythmias in patients with implantable defibrillators , 2017, Acta cardiologica.

[12]  S. Hsu,et al.  Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors , 2016, Scientific Reports.

[13]  A. Kleber,et al.  Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy. , 2016, JCI insight.

[14]  Stefania Rizzo,et al.  Arrhythmogenic cardiomyopathy , 2016, Orphanet Journal of Rare Diseases.

[15]  Y. Uchino,et al.  Galectin-3 as a regulator of the epithelial junction: Implications to wound repair and cancer , 2015, Tissue barriers.

[16]  J. Saffitz,et al.  Arrhythmogenic right ventricular cardiomyopathy mutations alter shear response without changes in cell-cell adhesion. , 2014, Cardiovascular research.

[17]  H. Calkins,et al.  Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy , 2014, Science Translational Medicine.

[18]  S. Stowell,et al.  Galectin-3 Regulates Desmoglein-2 and Intestinal Epithelial Intercellular Adhesion* , 2014, The Journal of Biological Chemistry.

[19]  A. Marian,et al.  The Hippo Pathway Is Activated and Is a Causal Mechanism for Adipogenesis in Arrhythmogenic Cardiomyopathy , 2014, Circulation research.

[20]  J. Saffitz,et al.  Remodeling of Cell-Cell Junctions in Arrhythmogenic Cardiomyopathy , 2014, Cell communication & adhesion.

[21]  J. Morales-Rull,et al.  Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. , 2013, International journal of cardiology.

[22]  H. Calkins,et al.  Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.

[23]  Cécile Boscher,et al.  Galectin-3 Protein Regulates Mobility of N-cadherin and GM1 Ganglioside at Cell-Cell Junctions of Mammary Carcinoma Cells* , 2012, The Journal of Biological Chemistry.

[24]  D. Corrado,et al.  Pathophysiology of arrhythmogenic cardiomyopathy , 2012, Nature Reviews Cardiology.

[25]  M. Akke,et al.  The Carbohydrate-Binding Site in Galectin-3 Is Preorganized To Recognize a Sugarlike Framework of Oxygens: Ultra-High-Resolution Structures and Water Dynamics , 2011, Biochemistry.

[26]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, Circulation.

[27]  A. Moorman,et al.  Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy , 2009, The Journal of experimental medicine.

[28]  D. Corrado,et al.  Arrhythmogenic right ventricular cardiomyopathy , 2009, The Lancet.

[29]  M. Hung,et al.  Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. , 2009, Cancer research.

[30]  S. Forbes,et al.  Regulation of Alternative Macrophage Activation by Galectin-31 , 2008, The Journal of Immunology.

[31]  Maurizio Schiavon,et al.  Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. , 2006, JAMA.

[32]  G. Danieli,et al.  Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. , 2006, European heart journal.

[33]  Michael D. Schneider,et al.  Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. , 2006, The Journal of clinical investigation.

[34]  J. Iredale,et al.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Kuwano,et al.  Implication of galectin-3 in Wnt signaling. , 2005, Cancer research.

[36]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[37]  R. Hughes.  Galectins as modulators of cell adhesion. , 2001, Biochimie.

[38]  A. Angelini,et al.  Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? , 1996, Circulation.

[39]  D. Corrado,et al.  Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.